Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1.

IF 2.5 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

World Journal of Gastrointestinal Oncology Pub Date : 2024-08-15 DOI:10.4251/wjgo.v16.i8.3521

Shin Woo Kang, Sung Hee Lim, Min-Ji Kim, Jeeyun Lee, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Seung Tae Kim

{"title":"Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1.","authors":"Shin Woo Kang, Sung Hee Lim, Min-Ji Kim, Jeeyun Lee, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Seung Tae Kim","doi":"10.4251/wjgo.v16.i8.3521","DOIUrl":null,"url":null,"abstract":"Background: Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, inhibits angiogenesis and reduces tumor growth. Serum VEGF-C, lactate dehydrogenase, and inflammatory markers have been reported as predictive markers related to bevacizumab treatment. Programmed cell death ligand 1 (PD-L1) could act upon VEGF receptor 2 to induce cancer cell angiogenesis and metastasis.Aim: To investigate the efficacy of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer (CRC) according to the expression of PD-L1.Methods: This analysis included CRC patients who received bevacizumab plus FOLFOX or FOLFIRI as first-line therapy between June 24, 2014 and February 28, 2022, at Samsung Medical Center (Seoul, South Korea). Analysis of patient data included evaluation of PD-L1 expression by the combined positive score (CPS). We analyzed the efficacy of bevacizumab according to PD-L1 expression status in patients with CRC.Results: A total of 124 patients was included in this analysis. Almost all patients were treated with bevacizumab plus FOLFIRI or FOLFOX as the first-line chemotherapy. While 77% of patients received FOLFOX, 23% received FOLFIRI as backbone first-line chemotherapy. The numbers of patients with a PD-L1 CPS of 1 or more, 5 or more, or 10 or more were 105 (85%), 64 (52%), and 32 (26%), respectively. The results showed no significant difference in progression-free survival (PFS) and overall survival (OS) with bevacizumab treatment between patients with PD-L1 CPS less than 1 and those with PD-L1 CPS of 1 or more (PD-L1 < 1% vs PD-L1 ≥ 1%; PFS: P = 0.93, OS: P = 0.33), between patients with PD-L1 CPS less than 5 and of 5 or more (PD-L1 < 5% vs PD-L1 ≥ 5%; PFS: P = 0.409, OS: P = 0.746), and between patients with PD-L1 CPS less than 10 and of 10 or more (PD-L1 < 10% vs PD-L1 ≥ 10%; PFS: P = 0.529, OS: P = 0.568).Conclusion: Chemotherapy containing bevacizumab can be considered as first-line therapy in metastatic CRC irrespective of PD-L1 expression.","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334044/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v16.i8.3521","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, inhibits angiogenesis and reduces tumor growth. Serum VEGF-C, lactate dehydrogenase, and inflammatory markers have been reported as predictive markers related to bevacizumab treatment. Programmed cell death ligand 1 (PD-L1) could act upon VEGF receptor 2 to induce cancer cell angiogenesis and metastasis.

Aim: To investigate the efficacy of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer (CRC) according to the expression of PD-L1.

Methods: This analysis included CRC patients who received bevacizumab plus FOLFOX or FOLFIRI as first-line therapy between June 24, 2014 and February 28, 2022, at Samsung Medical Center (Seoul, South Korea). Analysis of patient data included evaluation of PD-L1 expression by the combined positive score (CPS). We analyzed the efficacy of bevacizumab according to PD-L1 expression status in patients with CRC.

Results: A total of 124 patients was included in this analysis. Almost all patients were treated with bevacizumab plus FOLFIRI or FOLFOX as the first-line chemotherapy. While 77% of patients received FOLFOX, 23% received FOLFIRI as backbone first-line chemotherapy. The numbers of patients with a PD-L1 CPS of 1 or more, 5 or more, or 10 or more were 105 (85%), 64 (52%), and 32 (26%), respectively. The results showed no significant difference in progression-free survival (PFS) and overall survival (OS) with bevacizumab treatment between patients with PD-L1 CPS less than 1 and those with PD-L1 CPS of 1 or more (PD-L1 < 1% vs PD-L1 ≥ 1%; PFS: P = 0.93, OS: P = 0.33), between patients with PD-L1 CPS less than 5 and of 5 or more (PD-L1 < 5% vs PD-L1 ≥ 5%; PFS: P = 0.409, OS: P = 0.746), and between patients with PD-L1 CPS less than 10 and of 10 or more (PD-L1 < 10% vs PD-L1 ≥ 10%; PFS: P = 0.529, OS: P = 0.568).

Conclusion: Chemotherapy containing bevacizumab can be considered as first-line therapy in metastatic CRC irrespective of PD-L1 expression.

查看原文本刊更多论文

根据程序性细胞死亡配体 1，对转移性结直肠癌患者进行含有贝伐珠单抗的化疗的疗效。

背景介绍贝伐单抗是一种抗血管内皮生长因子（VEGF）的单克隆抗体，可抑制血管生成并减少肿瘤生长。据报道，血清血管内皮生长因子-C、乳酸脱氢酶和炎症指标是贝伐珠单抗治疗的相关预测指标。目的：根据 PD-L1 的表达，研究转移性结直肠癌（CRC）患者接受含贝伐单抗化疗的疗效：这项分析包括2014年6月24日至2022年2月28日期间在三星医疗中心（韩国首尔）接受贝伐单抗联合FOLFOX或FOLFIRI一线治疗的CRC患者。患者数据分析包括通过联合阳性评分（CPS）评估PD-L1的表达。我们根据 PD-L1 表达状态分析了贝伐单抗对 CRC 患者的疗效：结果：共有124名患者参与了此次分析。几乎所有患者都接受了贝伐单抗联合 FOLFIRI 或 FOLFOX 作为一线化疗。77%的患者接受了FOLFOX，23%的患者接受了FOLFIRI作为骨干一线化疗。PD-L1 CPS 为 1 或以上、5 或以上或 10 或以上的患者人数分别为 105 人（85%）、64 人（52%）和 32 人（26%）。结果显示，PD-L1 CPS小于1和PD-L1 CPS大于或等于1的患者在贝伐珠单抗治疗下的无进展生存期（PFS）和总生存期（OS）无明显差异（PD-L1 < 1% vs PD-L1 ≥ 1%；PFS：P = 0.93，OS：P = 0.33），在PD-L1 CPS小于5和大于5的患者之间（PD-L1 < 5% vs PD-L1 ≥ 5%；PFS：P = 0.409，OS：P = 0.746），以及在PD-L1 CPS小于10和大于10的患者之间（PD-L1 < 10% vs PD-L1 ≥ 10%；PFS：P = 0.529，OS：P = 0.568）：结论：无论PD-L1表达如何，含有贝伐珠单抗的化疗均可作为转移性CRC的一线疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Gastrointestinal Oncology Medicine-Gastroenterology

CiteScore

4.20

自引率

3.30%

发文量

1082

期刊介绍： The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.